ArticleFrontiers in endocrinology2025
Thermal ablation for ata intermediate-risk papillary thyroid carcinoma: efficacy and safety outcomes in a retrospective cohort.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of thermal ablation (TA) for ATA intermediate-risk papillary thyroid carcinoma (PTC). Methods and materials: This retrospective study analyzed ATA intermediate-risk PTC (either ultrasound extrathyroidal extension or cervical lymph node < 3cm metastasis) patients treated with TA at China-Japan Friendship Hospital between April 2018 and December 2023. Outcomes included technical success, recurrence-free survival (RFS), and complications. Multi-Cox regression identified prognostic factors. Results: A total of 113 people were included. TA demonstrated 100% technical success and complete ablation rates. 18 patients (15.9%) had developed tumor recurrence. The 1-, 3-, and 5-year RFS rates were 95.6%, 83.7%, and 79.8%, respectively. Metastatic lymph node diameter independently predicted progression (HR:3.20, Conclusions: TA shows promising efficacy and safety for selected ATA intermediate-risk PTC patients, with lymph node size as a key prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.